GW Pharmaceuticals Announces Full Exercise of Underwriters'

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
GW Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

LONDON, May 15, 2015 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH ) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces that the underwriters of its recently closed public offering on the NASDAQ Global Market have exercised in full their option to purchase an additional 240,000 American Depositary Shares ("ADSs") at a price to the public of $112.00 per ADS, raising additional net proceeds of approximately $25.3 million, after deducting underwriting discounts and commissions and estimated offering expenses. GW expects to deliver the additional 240,000 ADSs on or about May 20, 2015, subject to customary closing conditions.

Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as joint book-running managers for the offering. Piper Jaffray & Co. acted as lead manager.

The ADSs described above were offered by GW pursuant to a shelf registration statement filed by GW with the Securities and Exchange Commission ("SEC") that became automatically effective on May 7, 2014. The offering of the ADSs was made only by means of a prospectus and prospectus supplement. You may obtain these documents on the SEC's website at http://www.sec.gov . Alternatively, the prospectus and prospectus supplement may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; BofA Merrill Lynch, 222 Broadway, New York, NY 10038, attention: Prospectus Department, email: dg.prospectus_requests@baml.com ; Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

For readers in the European Economic Area

In any EEA Member State that has implemented the Prospectus Directive, this communication is only addressed to and directed at qualified investors in that Member State within the meaning of the Prospectus Directive. The term "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in each relevant Member State), together with any relevant implementing measure in the relevant Member State.

For readers in the United Kingdom

This communication, in so far as it constitutes an invitation or inducement to enter into investment activity (within the meaning of s21 Financial Services and Markets Act2000 as amended) in connection with the securities which are the subject of the offering described in this press release or otherwise, is being directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments who fall within Article 19(5) ("Investment professionals") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) certain high value persons and entities who fall within Article 49(2)(a) to (d) ("High net worth companies, unincorporated associations etc") of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together being referred to as "relevant persons"). The ADSs are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such ADSs will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex®, which is in Phase 3 clinical development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com .

Forward-looking statements

This news release may contain forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding the expected timing of the delivery of the option ADSs, the therapeutic benefit, safety profile and commercial value of the company's investigational drug Epidiolex®, the development and commercialization of Epidiolex, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex®, Epidiolex®, and other products, if approved, by consumer and medical professionals. A further list and description of risks, uncertainties and other risks associated with an investment in GW can be found in GW's filings with the U.S. Securities and Exchange Commission, including its shelf registration statement and the documents incorporated by reference therein. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Enquiries:  
   
GW Pharmaceuticals plc +44 20 3727 1000
Stephen Schultz, VP Investor Relations 917 280 2424 / 401 500 6570
   
FTI Consulting (Media Enquiries)  
Ben Atwell / Simon Conway / John Dineen (UK) + 44 20 3727 1000
Robert Stanislaro (U.S.) 212 850 5657
   
Trout Group, LLC (U.S. investor relations)  
Todd James / Chad Rubin 646 378 2900
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alphabet Lawsuit Puts Gemini Delays Under a Microscope

Updated Category News Views 99

July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...

Continue Reading
Kuaishou’s AI Push Meets a Brutal Earnings Reality

Updated Category News Views 133

Kuaishou just put a very expensive wrinkle in its AI story. The third-quarter figures are not a minor wobble: revenue dropped 11.1% year over year to RMB31.6 billion, gross margin slid from 54.7% to 48.2%, and the company swung from a RMB4.5 billion profit to a RMB959 million loss. For holders of 01024, that is the sort of earnings release that demands less daydreaming...

Continue Reading
Freedom Debt Relief Earns Service Recognition in 2026

Updated Category News Views 161

A Service Badge Carries Weight in a Rough Business Debt settlement is not a business where a pleasant phone voice alone gets the job done. People arrive carrying unsecured balances, anxiety, and usually a fair amount of distrust. That is why CNBC Select naming Freedom Debt Relief its “Best for Customer Service” is more meaningful than the usual chest-thumping...

Continue Reading
PenFed’s Toys for Tots Drive Targets Holiday Gift Gaps

Updated Category News Views 34

A missing present under a tree is not a statistic anybody ought to glide past. PenFed Credit Union has opened its annual Toys for Tots collection across Washington-region branches, taking new, unwrapped toys through December 8 at 1:00 p.m. ET. The useful detail, and frankly the one worth remembering when people default to buying the easiest shiny thing on a shelf, is...

Continue Reading
Blast Doubles Athabasca Ground, but Drills Still Matter

Updated Category News Views 75

More ground in Athabasca can wake up a uranium junior fast, and Blast Resources has certainly grabbed investors’ attention with this one. The company has optioned eight additional uranium claims beside its Wales Lake property in northern Saskatchewan, taking its regional footprint from 12,150 hectares across 16 claims to 30,732 hectares across 24 claims. That is more...

Continue Reading
Rafay's Third Fast 500 Nod Tracks AI Cloud Buildout

Updated Category News Views 51

GPU warehouses are easy to admire and brutally hard to operate like a real business. Rafay Systems landing on Deloitte's 2026 Technology Fast 500 for a third straight year is another signal that the AI infrastructure scramble has moved well beyond simply finding chips. Somebody has to turn all that expensive compute into services customers can provision, use, measure and...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 123

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
Sungrow Puts Storage Safety and Deployment on Display

Updated Category News Views 177

Fire-test footage is not usually the thing that grabs a room in Las Vegas, but Sungrow made it the centerpiece at RE+ 2026 for a reason. Energy storage has no shortage of glossy promises; what it needs is proof that equipment can handle the ugly stuff. Sungrow used the show to pitch a broader North American lineup, yet the PowerTitan 3.0 battery system and its large-scale...

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 183

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 93

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading

Top 5 Most Recently Viewed Articles

10 Strategies for Real Estate Investors: Stay Ahead of Risks

Updated Category Real Estate Views 1172

Introduction: 10 Easy Tips for Smart Property Investors Are you inve­sting in real estate? Pre­pare ahead to avoid costly surprises down the­ road. Imagine buying a property only to learn about hidde­n issues later. Wouldn't it be be­tter to anticipate risks early on? In re­al estate, staying informed can make­ or break your success. That's why this guide will help...

Continue Reading
Investors Show Strong Interest in Nike Options Trading Activity

Updated Category News Views 181

Market Whales and Their Recent Bets on NKE Options Recently, there has been significant interest among prominent investors in Nike, showcasing a bullish attitude toward the stock. Analyzing Options Trades for Nike (NYSE: NKE) Upon reviewing Nike's options history, we've identified multiple trades that reflect a notable trend. A clear majority of 50% of these trades have...

Continue Reading
AdTech Holding Celebrates Prestigious Workplace Certification

Updated Category News Views 176

AdTech Holding Achieves Recognition for Workplace Excellence AdTech Holding has recently earned the esteemed Great Place To Work® Certification™ for the third consecutive year. This notable achievement reflects the genuine feedback from employees concerning the workplace culture, trust, and the opportunities for professional growth that the company fosters. A...

Continue Reading
Innovative Truck Bed Design Revolutionizes Hauling for Drivers

Updated Category News Views 285

Enhancing Pickup Truck Hauling with Innovative Designs Many truck owners often face the challenge of maximizing their vehicle's hauling capabilities, especially when it comes to transporting large loads. One inventive solution that rises to this challenge is the BRIELLA TRUCK BEDS. This innovative design allows pickup trucks to convert effectively into flatbed trucks,...

Continue Reading
Investigation on Behalf of Long-Term Shareholders of Multiple Companies

Updated Category News Views 131

Investigation Into Geron Corporation and Other Companies Johnson Fistel, PLLP is conducting an investigation into potential violations of both federal and state securities laws. This inquiry focuses on the actions of certain officers and directors within Geron Corporation, Viatris Inc., Everus Construction Group, Inc., and SoundHound AI, Inc. Shareholders, particularly...

Continue Reading